Download Gene Section FXYD5 (FXYD domain containing ion transport regulator 5)

Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Mini Review
FXYD5 (FXYD domain containing ion transport
regulator 5)
Setsuo Hirohashi
Pathology Division, National Cancer Center Research Institute 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045,
Japan (SH)
Published in Atlas Database: July 2008
Online updated version : http://AtlasGeneticsOncology.org/Genes/FXYD5ID40652ch19q13.html
DOI: 10.4267/2042/44488
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2009 Atlas of Genetics and Cytogenetics in Oncology and Haematology
Identity
Homology
Other names: DYSAD; Dysadherin; HSPC113; IWU1; IWU1; KCT1; OIT2; PRO6241; RIC; UNQ2561
HGNC (Hugo): FXYD5
Location: 19q13.12
The transmembrane domain of dysadherin and mouse
RIC especially showed a very high degree of similarity
to other ion channels such as Mat-8 chloride channel,
phospholemman, which is the major plasma membrane
substrate for cAMP dependent protein kinase and
protein kinase C, and the subunit of Na, K-ATPase.
DNA/RNA
Implicated in
Transcription
Various cancers
0.9 kb mRNA; 534 bp open reading frame.
Disease
Dysadherin, newly identified cell membrane
glycoprotein, downregulates E-cadherin and promotes
cancer invasion and metastasis. A reverse correlation
between dysadherin expression and E-cadherin
expression was observed in various cancers. Increased
dysadherin expression was correlated with poor
prognosis with head and neck squamous cell
carcinoma, esophageal carcinoma, gastric carcinoma,
colorectal carcinoma, melanoma and so on. Dysadherin
expression in epitheloid sarcomas could be a used as
powerful diagnostic marker for distinguishing
epithelioid sarcomas from malignant rabdoid tumors.
Protein
Dysadherin protein consists of 178 amino acids.
Description
The deduced amino acid sequence consisted of two
hydrophobic regions corresponding to a signal peptide
and a transmembrane domain (146-162), a serine-,
threonine-, and proline-rich extracellular domain,
which is a target for O-glycosylation, anda short
cytoplasmic region containing positively charged
amino acid residues.
References
Expression
Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S.
Dysadherin, a cancer-associated cell membrane glycoprotein,
down-regulates E-cadherin and promotes metastasis. Proc
Natl Acad Sci U S A. 2002 Jan 8;99(1):365-70
Endothelial cell, T lymphocytes, basal cell of squamous
epithelium.
Localisation
Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato
Y, Kitajima M, Sakamoto M, Hirohashi S. Prognostic
significance of dysadherin expression in advanced colorectal
carcinoma. Br J Cancer. 2003 Mar 10;88(5):726-32
Cell membrane.
Atlas Genet Cytogenet Oncol Haematol. 2009; 13(6)
413
FXYD5 (FXYD domain containing ion transport regulator 5)
Hirohashi S
Hirohashi S, Kanai Y. Cell adhesion system and human cancer
morphogenesis. Cancer Sci. 2003 Jul;94(7):575-81
Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y,
Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K.
Expression patterns of dysadherin and E-cadherin in lymph
node metastases of colorectal carcinoma. Virchows Arch. 2006
Jun;448(6):763-7
Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S.
Dysadherin: expression and clinical significance in thyroid
carcinoma. J Clin Endocrinol Metab. 2003 Sep;88(9):4407-12
Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Iwasaki H, Sonobe
H, Goto H, Kusakabe H, Takahira T, Kobayashi C, Kawaguchi
K, Saito T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M.
Prognostic significance of dysadherin expression in epithelioid
sarcoma and its diagnostic utility in distinguishing epithelioid
sarcoma from malignant rhabdoid tumor. Mod Pathol. 2006
Jun;19(6):820-31
Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K,
Kosuge T, Sekihara H, Hirohashi S. Dysadherin
overexpression in pancreatic ductal adenocarcinoma reflects
tumor aggressiveness: relationship to e-cadherin expression. J
Clin Oncol. 2003 Feb 15;21(4):659-67
Tsuiji H, Takasaki S, Sakamoto M, Irimura T, Hirohashi S.
Aberrant O-glycosylation inhibits stable expression of
dysadherin, a carcinoma-associated antigen, and facilitates
cell-cell adhesion. Glycobiology. 2003 Jul;13(7):521-7
Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y,
Hirohashi S, Charalabopoulos K. Dysadherin expression in
head and neck squamous cell carcinoma: association with
lymphangiogenesis and prognostic significance. Am J Surg
Pathol. 2006 Feb;30(2):185-93
Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M,
Hirohashi S. Prognostic significance of dysadherin expression
in tongue cancer: immunohistochemical analysis of 91 cases.
Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):323-8
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA,
Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM.
Chemokine (C-C motif) ligand 2 mediates the prometastatic
effect of dysadherin in human breast cancer cells. Cancer Res.
2006 Jul 15;66(14):7176-84
Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T,
Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto
M, Hirohashi S, Imamura M. Prognostic significance of
dysadherin expression in esophageal squamous cell
carcinoma. Oncology. 2004;67(1):73-80
Batistatou A, Makrydimas G, Zagorianakou N, Zagorianakou P,
Nakanishi Y, Agnantis NJ, Hirohashi S, Charalabopoulos K.
Expression of dysadherin and E-cadherin in trophoblastic
tissue in normal and abnormal pregnancies. Placenta. 2007
May-Jun;28(5-6):590-2
Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J,
Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S,
Imamura M. Clinical significance of dysadherin expression in
gastric cancer patients. Clin Cancer Res. 2004 Apr
15;10(8):2818-23
Batistatou A, Peschos D, Tsanou H, Charalabopoulos A,
Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K. In
breast carcinoma dysadherin expression is correlated with
invasiveness but not with E-cadherin. Br J Cancer. 2007 May
7;96(9):1404-8
Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A,
Nakajima A, Sakamoto M, Kanai Y, Hirohashi S. Dysadherin
expression facilitates cell motility and metastatic potential of
human pancreatic cancer cells. Cancer Res. 2004 Oct
1;64(19):6989-95
Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown
RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons
PG, Jans DA, Waters MJ. Nuclear targeting of the growth
hormone receptor results in dysregulation of cell proliferation
and tumorigenesis. Proc Natl Acad Sci U S A. 2007 Aug
14;104(33):13331-6
Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland
JM, Suo Z. Prognostic significance of dysadherin expression in
cervical squamous cell carcinoma. Pathol Oncol Res.
2004;10(4):212-8
Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe
H, Takahira T, Kobayashi C, Yamamoto H, Tamiya S,
Hirohashi S, Iwamoto Y, Tsuneyoshi M. Dysadherin expression
as a significant prognostic factor and as a determinant of
histologic features in synovial sarcoma: special reference to its
inverse relationship with E-cadherin expression. Am J Surg
Pathol. 2007 Jan;31(1):85-94
Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y,
Toge T, Sugano K, Hirohashi S. Establishment of two cell lines
from human gastric scirrhous carcinoma that possess the
potential to metastasize spontaneously in nude mice. Cancer
Sci. 2004 Jul;95(7):575-82
Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y,
Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S.
Clinicopathologic significance of dysadherin expression in
cutaneous malignant melanoma: immunohistochemical
analysis of 115 patients. Cancer. 2005 Apr 15;103(8):1693-700
Nam JS, Hirohashi S, Wakefield LM. Dysadherin: a new player
in cancer progression. Cancer Lett. 2007 Oct 8;255(2):161-9
This article should be referenced as such:
Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami
Hirohashi S. FXYD5 (FXYD domain containing ion transport
regulator 5). Atlas Genet Cytogenet Oncol Haematol. 2009;
13(6):413-414.
K, Oda M, Watanabe G. Prognostic significance of dysadherin
expression in patients with non-small cell lung cancer. J
Thorac Cardiovasc Surg. 2005 Sep;130(3):740-5
Atlas Genet Cytogenet Oncol Haematol. 2009; 13(6)
414